Walking into Servier's office in Beijing's CBD, **wall** catches your eye is a black and white photo taken in 1980 on the "Chinese Forensic Medicine Day". Standing in the middle of the group photo is the then vice premier of the country, standing on the left is the French cardiovascular surgeon Leger, and on the right is the representative of Servier Group, Wang Huacan, who is also the first chairman of Servier (Tianjin) Pharmaceutical. 
*Provided by Servier and may not be **or** without Servier's authorization.
The yellowed photo paper tells everyone who stops here the traces of the years they have experienced.
As China's first Sino-French medical exchange program, both China and France attach great importance to this exchange, and the then Prime Minister of the French Republic, Barr, served as the honorary chairman of the French side of the Medical Day event, and the honorary chairman of the Chinese side was the chief architect of China's reform and opening up
After months of planning, in April 1980, the Chinese Medical Association, France's second largest pharmaceutical company, Servier and Air France's medical department jointly founded China's first Sino-French medical exchange program, which promoted academic exchanges between Chinese and French medical experts in the fields of cardiology, endocrinology, neuropsychiatry, etc., and became a successful model of Sino-French exchanges that began in the early days of reform and opening up.
The Servier Group is one of the few independent multinational pharmaceutical groups in the world. Its organizational structure is unique – it has no shareholders, it is independent without going public, and it is managed by a non-profit** company that manages its business worldwide.
Just like the story behind **, Servier is one of the first multinational pharmaceutical companies to enter China. In 1979, Servier submitted and obtained an import license to introduce original products such as gliclazide tablets, a type 2 diabetes drug, into the Chinese market, becoming the first batch of multinational pharmaceutical companies to come to China.
Entering 2024, on the occasion of the 60th anniversary of the establishment of diplomatic relations between China and France, Servier celebrates his 45th birthday in China. At a moment when history and corporate development have reached a landmark juncture, how will Servier write the next chapter?
Maintain the leadership advantage of chronic diseases and focus on tumor transformation
In the days of reform and opening up, the core of Servier China's business has always been focused on the fields of heart health, hypertension, diabetes and oncology, bringing best-in-class or first-in-class innovative original drugs to Chinese patients, while constantly adjusting to meet the country's centralized procurement policy and the challenges from generic drugs.
Founded in 1954, Servier Group is the world's third largest pharmaceutical group in the field of chronic diseases in the field of heart disease and hypertension. In the 70s of the last century, Servier launched a second-generation sulfonylurea hypoglycemic drug gliclazide, which is also the earliest imported hypoglycemic drug introduced after China's reform and opening up. At that time, Sinopharm Tianjin Company imported gliclazide and required a large amount of foreign exchange. In order to save foreign exchange, it was decided to import raw materials to be processed into preparations, which were produced by Huajin Pharmaceutical and sold by Sinopharm Tianjin Company. Gliclaclazide extended-release tablets have since been produced in China.
In the 80s, Servier also provided China with the cerebrovascular ** drug amitriazine mesylate carocarpacine, which filled the gap in China. Between 1998 and 2003, Servier introduced six new drugs, including the heart drug metazide tablets "Wanshuangli", and the hypertension drug perindopril tert-butylmine tablets "Yashida" into the Chinese market.
Over the past 45 years since entering China, Servier has always maintained its leading position in the cardiovascular and metabolic industry. In the areas of cardiology, hypertension and venous health, Servier continues to expand its channels and continue to promote the accessibility of the Group's original drugs to Chinese patients, strengthening its advantages and maintaining its leading position.
Taking typical chronic diseases such as hypertension as an example, Servier has carried out a number of cooperative projects for community hospitals to promote communication and interaction between patients and doctors, so as to strengthen the management of patients' chronic diseases and promote the control of diseases in the community. In retail pharmacies, Servier products are sold in more than 200,000 stores in China, helping patients to access medicines more conveniently. Servier China has also established strategic partnerships with e-commerce and internet hospital platforms such as Alibaba Health and JD.com. These deep market explorations, through joint efforts with local partners, have effectively reduced the burden on patients and improved the best results.
"Focus" appears several times in Servier's strategic description. As defined in the 2030 strategy set out by the Servier Group in 2022: to be a medium-sized, focused and innovative company in the fields of oncology, neuroscience and immunoinflammation.
In line with the Group's strategic planning process, Servier plans to achieve a revenue target of at least EUR 3 billion in oncology by 2030, which is key to Servier's transformational development and strategic growth. To this end, the Group's position in the field of oncology has been significantly strengthened over the past four years with investments of more than 6 billion euros. At the same time, in recent years, Servier has invested 50% of its R&D budget in the field of oncology, and the R&D direction mainly revolves around immunity and targeting. At present, Servier has 39 R&D projects and 7 marketed drugs in oncology, covering hematological malignancies and solid tumors, including gastric cancer, intestinal cancer, lung cancer and other cancer types.
Let China be a participant and leader in innovation
In April 2022, Servier's first drug, Eanda, was approved in China. For Chinese pancreatic cancer patients who have not had a new ** regimen approved for 23 years, the approval of Yianda has broken the dilemma that there is no ** regimen for pancreatic cancer approved in China after gemcitabine was approved for pancreatic cancer indication in 1999, and has brought innovative solutions to pancreatic cancer patients.
Under the vision of "becoming an outstanding contributor in the field of oncology", Servier China has laid out a rich product pipeline in refractory tumors, including colorectal cancer, central nervous system tumors, etc., bringing more diverse choices to patients and improving the quality of life.
Just this past December, Servier completed a transaction with CStone Pharmaceuticals to acquire the exclusive commercialization rights of ivosidenib tablets in Greater China and Singapore. Ivosidenib tablets are currently the first and only approved target for patients with IDH1 susceptibility mutations or refractory AML**. In China, based on urgent clinical needs, ivosidenib tablets were included in the "List of Overseas New Drugs Urgently Needed for Clinical Purposes (Third Batch)". In January 2022, ivosidenib tablets were conditionally approved by the NMPA through the priority review and approval process, bringing a new solution to patients with IDH1 mutations** or refractory acute myeloid leukemia (AML).
In Servier's view, this acquisition will strengthen Servier China's leading position in IDH1 mutations and promote Servier to provide groundbreaking** solutions for local patients with rare and refractory cancers.
This acquisition is an important step in the expansion of Servier's ambition in the field of oncology**, and this milestone underscores Servier's commitment to strengthening its oncology business in China and serving cancer patients worldwide.
In recent years, China has been firmly in the top three positions in the market with the largest contribution to the performance of Servier Group, and the strong performance has given Servier the confidence to continue to tilt resources and focus, and the huge development potential of the Chinese market is also feeding back the global new drug research and development capabilities.
Today's Chinese market is not only one of the most important strategic markets for Servier in the world, but also the first country outside of Servier's headquarters in France to have a complete drug development and commercialization function.
In the process of new drug research and development, Servier aims to promote China to become a "participant" and "leader" in the simultaneous research and development of new drugs in the world: on the one hand, it hopes that more world-first products can be approved and marketed in China to help patients, and at the same time, it also hopes that through China's participation, it can help Servier improve the speed of global research and development and benefit more patients around the world. In addition, it is worth noting that China has become the "pioneer" of Servier Group in the fields of participating in global clinical research projects and digital innovation.
Servier chose to include China in the early R&D deployment of the headquarters. In a global international multi-center phase III study of a colorectal cancer product, Chinese patients were included in the global trial through the model of multi-regional clinical trial (MRCT). In addition, for foreign products that have carried out international multi-center registration phase studies, such as the world's first product under development for patients with low-grade glioma, Schwiysch has been bridging to global clinical trials through small sample size efficacy and safety studies, which is also a synergy with global R&D. At present, the drug has been submitted for the review and application of new drug clinical research in China.